scholarly journals FORMULATION DEVELOPMENT AND EVALUATION OF CLOZAPINE TRANSDERMAL PATCHES

2021 ◽  
pp. 204-207
Author(s):  
Pratik P. Patel ◽  
Priyal M. Raval
Keyword(s):  
Clinical Study ◽  
Schizoaffective Disorder ◽  
Suicidal Behaviour ◽  
Therapeutic Interventions ◽  
Positive Symptoms ◽  
Keywords Schizophrenia ◽  
Formulation Development ◽  
Transdermal Patches ◽  
Experimental Process ◽  
Second Generation Antipsychotic

The Clozapine is available in the form of 25 Yellow Tablets of 100mg. Clozapine is very famous in now-a-days due to its use of optimisation in transdermal metric basically for experimental process and design.it is used for the improvement of bioavailability. The medications are demonstrated for mitigating the risk of recurrent suicidal behaviour in schizophrenia patients or schizoaffective disorder who really are evaluated to be at persistent risk of convolutional suicidal behaviour in a historical and controlled experimental state. The paper provides a brief analysis of Clozapine drugs Usage, Formulation and Evaluation. The drugs were used upon animals at first to test the effects. There are several side effects of Clozapine that includes High fever and also symptoms like flu, Weakness and dizziness, allergy in skin and red spots, Sometimes itching problems in vaginal, in serious problems it can also create breathing problems and worsening cough. This is known as the Second Generation Antipsychotic that helps in balancing the dopamine and serotonin that improves the cognitive functions like mood, thinking and behaviour of an individual. Clozapine is restricted to use however it is used under one particular condition i.e. when the person suffering from Schizophrenia does not respond to other medications, have suicidal incidents or have positive symptoms. Furthermore, considerable clinical study has proven that clozapine seems to be more efficacious than just about any other antipsychotic drug throughout therapeutic interventions and therefore it clearly outperforms some other antipsychotics with in treatment of recurrent schizoaffective disorder. KEYWORDS: schizophrenia, transdermal, clozapine, antipsychotic

scholarly journals Paliperidone to Treat Psychotic Disorders

2021 ◽  
Vol 13 (3) ◽  
pp. 343-358
Author(s):  
Hormazd D. Minwalla ◽  
Peter Wrzesinski ◽  
Allison Desforges ◽  
Joshua Caskey ◽  
Brittany Wagner ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Schizoaffective Disorder ◽  
Negative Symptoms ◽  
Psychotic Disorders ◽  
Drug Information ◽  
The United States ◽  
Mental Illnesses ◽  
Positive Symptoms ◽  
Review Of The Literature ◽  
Second Generation Antipsychotics

Purpose of Review: This is a comprehensive review of the literature regarding the use of paliperidone in the treatment of schizophrenia and schizoaffective disorder. It covers the background and presentation of schizophrenia and schizoaffective disorder, as well as the mechanism of action and drug information for paliperidone. It covers the existing evidence of the use of paliperidone for the treatment of schizophrenia and schizoaffective disorder. Recent Findings: Schizophrenia and schizoaffective disorder lead to significant cognitive impairment. It is thought that dopamine dysregulation is the culprit for the positive symptoms of schizophrenia and schizoaffective disorder. Similar to other second-generation antipsychotics, paliperidone has affinity for dopamine D2 and serotonin 5-HT2A receptors. Paliperidone was granted approval in the United States in 2006 to be used in the treatment of schizophrenia and in 2009 for schizoaffective disorder. Summary: Schizophrenia and schizoaffective disorder have a large impact on cognitive impairment, positive symptoms and negative symptoms. Patients with either of these mental illnesses suffer from impairments in everyday life. Paliperidone has been shown to reduce symptoms of schizophrenia and schizoaffective disorder.

Early formulation development of CKD-519, a new CETP inhibitor, for phase 1 clinical study based on in vitro and in vivo evaluation

2018 ◽  
Vol 549 (1-2) ◽  
pp. 388-396 ◽  
Author(s):  
Shin Jung Park ◽  
Prakash Thapa ◽  
Hye-Jin Seo ◽  
Eun Seok Park ◽  
Seong Hoon Jeong
Keyword(s):  
Clinical Study ◽  
Phase 1 ◽  
Formulation Development ◽  
In Vivo Evaluation ◽  
Cetp Inhibitor ◽  
Early Formulation

scholarly journals Transdermal patches: Design and current approaches to painless drug delivery

2019 ◽  
Vol 69 (2) ◽  
pp. 197-215 ◽  
Author(s):  
Othman A. Al Hanbali ◽  
Haji Muhammad Shoaib Khan ◽  
Muhammad Sarfraz ◽  
Mosab Arafat ◽  
Shakeel Ijaz ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Oral Drug Delivery ◽  
Hepatic Metabolism ◽  
Enzymatic Digestion ◽  
Assessment Tools ◽  
Oral Drug ◽  
Formulation Development ◽  
Transdermal Patches ◽  
Cardiac Disorders

Abstract Use of transdermal patches can evade many issues associated with oral drug delivery, such as first-pass hepatic metabolism, enzymatic digestion attack, drug hydrolysis and degradation in acidic media, drug fluctuations, and gastrointestinal irritation. This article reviews various transdermal patches available in the market, types, structural components, polymer role, and the required assessment tools. Although transdermal patches have medical applications for smoking cessation, pain relief, osteoporosis, contraception, motion sickness, angina pectoris, and cardiac disorders, advances in formulation development are ongoing to make transdermal patches capable of delivering more challenging drugs. Transdermal patches can be tailored and developed according to the physicochemical properties of active and inactive components, and applicability for long-term use. Therefore, a number of chemical approaches and physical techniques for transdermal patch development are under investigation.

Formulation development of matrix type transdermal patches containing mefenamic acid: physicochemical characterization and in vitro release evaluation

2017 ◽  
Vol 148 (7) ◽  
pp. 1215-1222 ◽  
Author(s):  
Jirapornchai Suksaeree ◽  
Kotchakorn Piamsap ◽  
Supawan Paktham ◽  
Tichakorn Kenprom ◽  
Chaowalit Monton ◽  
...  
Keyword(s):  
Mefenamic Acid ◽  
In Vitro Release ◽  
Physicochemical Characterization ◽  
Formulation Development ◽  
Matrix Type ◽  
Transdermal Patches ◽  
Vitro Release

scholarly journals Therapeutic Interventions in Oral Submucous Fibrosis: An Experimental and Clinical Study

2014 ◽  
Vol 14 (2) ◽  
pp. 278-290 ◽  
Author(s):  
Vibha Singh ◽  
Shadab Mohammad ◽  
A. P. Pant ◽  
C. S. Saimbi ◽  
Ritesh Srivastava
Keyword(s):  
Clinical Study ◽  
Oral Submucous Fibrosis ◽  
Therapeutic Interventions ◽  
Submucous Fibrosis

Conceptual and Ethical Issues in the Prodromal Phase of Psychosis

2013 ◽  
Author(s):  
Matthew Broome ◽  
Paolo Fusar-Poli ◽  
Philippe Wuyts
Keyword(s):  
Clinical Study ◽  
Ethical Issues ◽  
Risk Estimation ◽  
Neurodevelopmental Disorder ◽  
Research Work ◽  
Signs And Symptoms ◽  
Therapeutic Interventions ◽  
Prodromal Stage ◽  
Prodromal Phase ◽  
Ethical Concerns

Our focus in this chapter is to address some of the philosophical issues that arise in the scientific and clinical study of the prodromal phase of psychosis. We discuss issues from both metaphysics and philosophy of science as we all as those related to phenomenological approaches and clinical ethics. A clear challenge arises in considering how models of a continuum of psychosis and of schizophrenia as a neurodevelopmental disorder can be reconciled with a scientific understanding of the prodrome as a discrete constellation of signs and symptoms. Clinical and research work on the prodromal stage of psychosis also highlights ethical concerns. Demarcating a mental disorder and applying therapeutic interventions, based solely on risk estimation, should not be carried out lightly.

Patient Psychopathology and Expressed Emotion in Schizophrenia

1990 ◽  
Vol 157 (6) ◽  
pp. 877-880 ◽  
Author(s):  
Shirley M. Glynn ◽  
Eugenia T. Randolph ◽  
Spencer Eth ◽  
George G. Paz ◽  
Gregory B. Leong ◽  
...  
Keyword(s):  
Schizoaffective Disorder ◽  
Negative Symptoms ◽  
Expressed Emotion ◽  
Psychiatric Symptoms ◽  
Full Range ◽  
Positive Symptoms ◽  
Anxious Depression ◽  
Relationship Of ◽  
The Relationship

The relationship of a full range of psychiatric symptoms to EE was examined in 40 men with BPRS and SANS diagnoses of schizophrenia or schizoaffective disorder. Patients from high-EE families had significantly higher ratings of positive symptoms, anxious depression, and overall psychopathology, but not negative symptoms, than did those from low-EE families. In predicting relapses of schizophrenia, account may need to be taken of an interaction between subtle differences in symptoms and relatives' attitudes.

scholarly journals Evaluation of the efficacy of Shiva modaka on Hematological, Biochemical and Immunological Parameters in the management of malnutrition among school going children

2020 ◽  
Vol 5 (01) ◽  
Author(s):  
Pradeep EK ◽  
Ravishankar Shenoy
Keyword(s):  
Clinical Study ◽  
Adverse Effects ◽  
Protein Energy Malnutrition ◽  
Therapeutic Interventions ◽  
Early Age ◽  
Short Term ◽  
Immunological Parameters ◽  
Protein Energy ◽  
Early Schooling

Malnutrition is an issue of global dimensions affecting all ages. Malnutrition in children is common in early age especially during infancy and weaning. However, it also prevails during early schooling. In adults and elderly it is studied as under Protein Energy Malnutrition. It has not only short term adverse effects but also exhibits long term sustained and progressive effects. Kuposhana/Bala Shosha is explained in the Ayurveda literatures and elaborate therapeutic interventions are also described. The disease Karshya also applies to this condition. Shiva Modaka, a drug described under Bala Roga seems to act on vide dimensions of pediatric health with indications in common pediatric ailments too. The present clinical study is an effort to evaluate the efficacy of the said drug on hematological, biochemical and immunological parameters in Malnutrition in school going children.

Management of schizophrenia symptoms: Implications for recreation therapy

2008 ◽  
Vol 7 (3) ◽  
pp. 40
Author(s):  
Chris M. Dixon, MSc
Keyword(s):  
Depressive Symptoms ◽  
Negative Symptoms ◽  
Sense Of Self ◽  
Therapeutic Interventions ◽  
Psychotic Symptoms ◽  
Positive Symptoms ◽  
Recreation Therapy ◽  
Sensory Experiences ◽  
Effective Interventions ◽  
High Level

Effective interventions for the management of schizophrenia symptoms have been identified in the literature and have implication for recreation therapy. To prevent enduring negative symptoms that impact cognition, a high level of engagement in daily activity is recommended. Therapeutic interventions that show promise in reducing negative symptoms include participation in art, craft, music, and physical activity. To reduce high rates of distress and anxiety symptoms that exacerbate psychotic symptoms, animal assisted therapy, sensory experiences, and spiritual engagement were found to be effective. Early therapeutic intervention to rediscover a skill, talent, or hobby that establishes a sense of self and social identity may assist with reducing positive symptoms. Self-managed coping strategies such as distracting techniques may reduce auditory hallucinations. As positive symptoms reduce, a reduction of comorbid depressive symptoms may also occur. With reduction of negative and positive symptoms, as well as comorbid distress, anxiety, and depressive symptoms, individuals have an increased opportunity to attain their social and leisure goals.

Sign in / Sign up

Export Citation Format

Share Document